Atrial Natriuretic Factor Receptors (Atrial Natriuretic Factor Receptor)

Cell surface proteins that bind ATRIAL NATRIURETIC FACTOR with high affinity and trigger intracellular changes influencing the behavior of cells. They contain intrinsic guanylyl cyclase activity.

Also Known As:

Atrial Natriuretic Factor Receptor; Receptors, Atrial Natriuretic Factor; Atrial Natriuretic Peptides Receptor; Receptors, ANP; Receptors, Atrial Natriuretic Peptides; Receptor, ANF; Receptor, ANP; ANF Receptor; ANF Receptors; ANP Receptor; ANP Receptors; Atrial Natriuretic Peptides Receptors; Atriopeptin Receptors; Receptors, ANF; Receptors, Atriopeptin

Networked: 107 relevant articles (2 outcomes, 15 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kuhn, Michaela: 4 articles (01/2020 - 11/2002)
2.	Baba, Hideo A: 3 articles (09/2014 - 11/2002)
3.	Adeghate, Ernest: 2 articles (11/2006 - 06/2004)
4.	Adem, Abdu: 2 articles (11/2006 - 06/2004)
5.	Benedict, Sheela: 2 articles (11/2006 - 06/2004)
6.	van Eickels, Martin: 2 articles (01/2004 - 05/2003)
7.	Ströhle, A: 2 articles (11/2003 - 03/2003)
8.	Holtwick, Rita: 2 articles (05/2003 - 11/2002)
9.	Braunger, Barbara M: 1 article (01/2020)
10.	Heinze, Katrin G: 1 article (01/2020)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/01/1994 - "To further test the role of ANP in glomerular hyperfiltration, an ANP receptor antagonist was infused into anesthetized BB/DP rats (n = 10) 14 days after onset of IDDM, after baseline measurements of mean arterial pressure, renal hemodynamics, and renal fluid and electrolyte excretions. " 01/01/1992 - "Resting ANP levels were not significantly different in IDDM (34.9 +/- 11.3 pg/ml), NIDDM (42.6 +/- 11.7 pg/ml) or control subjects (40.9 +/- 17.2 pg/ml) however the infusion of saline resulted in a significantly greater increase of plasma ANP in the NIDDM patients (to 82.9 +/- 43.2 pg/ml; P < 0.01) than in the controls (55.6 +/- 23.7 pg/ml; P < 0.01) which was associated with a significantly less increase in sodium excretion (UNAV) in the NIDDM patients (+86% vs. 3170%; P < 0.02) indicating down-regulation of ANP receptors in the kidney of NIDDM patients.(ABSTRACT TRUNCATED AT 250 WORDS)"
2.	Anxiety Disorders (Anxiety Disorder) 03/01/2003 - "Furthermore, preclinical and clinical data on its anxiolytic activity suggest that nonpeptidergic ANP receptor ligands may be potentially useful in the treatment of anxiety disorders. " 11/01/2003 - "Furthermore, preclinical and clinical data on its anxiolytic activity suggest that non-peptidergic ANP receptor ligands may be of potential use in the treatment of anxiety disorders. "
3.	Type 2 Diabetes Mellitus (MODY) 01/01/1992 - "Resting ANP levels were not significantly different in IDDM (34.9 +/- 11.3 pg/ml), NIDDM (42.6 +/- 11.7 pg/ml) or control subjects (40.9 +/- 17.2 pg/ml) however the infusion of saline resulted in a significantly greater increase of plasma ANP in the NIDDM patients (to 82.9 +/- 43.2 pg/ml; P < 0.01) than in the controls (55.6 +/- 23.7 pg/ml; P < 0.01) which was associated with a significantly less increase in sodium excretion (UNAV) in the NIDDM patients (+86% vs. 3170%; P < 0.02) indicating down-regulation of ANP receptors in the kidney of NIDDM patients.(ABSTRACT TRUNCATED AT 250 WORDS)"
4.	Heart Failure 03/01/1995 - "The aim of the present studies was to investigate whether renal ANF receptor regulation in chronic heart failure is a time related event. " 03/01/1995 - "Downregulation of glomerular ANF receptors is a transient event during the development of high output heart failure in the rat. " 03/01/1995 - "Transient downregulation of glomerular atrial natriuretic factor receptors in high output heart failure in the rat." 09/01/1993 - "Glomerular atrial natriuretic factor receptors in experimental congestive heart failure." 07/01/1993 - "Regulation of renal glomerular and papillary ANP receptors in rats with experimental heart failure."
5.	Cardiomyopathies (Cardiomyopathy) 12/01/1995 - "Renal atrial natriuretic factor receptors in hamster cardiomyopathy." 12/01/1995 - "These results demonstrate that renal ANF receptors do not contribute to the attenuated renal responses to ANF in hamster cardiomyopathy." 12/01/1995 - "These studies were undertaken to fully characterize renal ANF receptor subtypes in normal hamsters and to evaluate whether alterations in renal ANF receptors may contribute to renal resistance to ANF in cardiomyopathy. " 07/01/1996 - "These studies were designed to characterize the atrial natriuretic peptide (ANF) receptor subtypes [guanylyl cyclase natriuretic peptide receptors (NPR-A, NPR-B) and NPR-C] in lungs of normal hamsters and to evaluate alterations in receptor kinetics in genetic cardiomyopathy (CMO), a model of human congestive heart failure. "

Related Drugs and Biologics

1.	Atrial Natriuretic Factor (ANF)
2.	Sodium
3.	Ligands
4.	Anti-Anxiety Agents (Anxiolytics)
5.	Guanylate Cyclase (Guanylyl Cyclase)
6.	Atrial Natriuretic Factor Receptors (Atrial Natriuretic Factor Receptor)
7.	Salts
8.	Proteins (Proteins, Gene)
9.	Peptides (Polypeptides)
10.	Natriuretic Peptides

Related Therapies and Procedures

1.	Surgical Instruments (Clip)
2.	Caloric Restriction